GE Healthcare IT, a division of General Electric Company, has signed a partnership agreement with M Modal, a provider of advanced speech understanding solutions, to deliver the next generation of radiology reporting technology.
Arpida has announced that the FDA has accepted for review the new drug application for intravenous iclaprim in the treatment of complicated skin and skin structure infections.
Wyeth Pharmaceuticals has announced that Pristiq, a new serotonin-norepinephrine reuptake inhibitor approved to treat adult patients with major depressive disorder, is now available in US retail pharmacies.
Allos Therapeutics has reported positive interim response and safety data from the company's pivotal Phase II Propel trial of PDX in patients with relapsed or refractory peripheral T-cell lymphoma.
Debiopharm Group has signed a license agreement with its long-term European pharmaceutical partner, for the marketing of Salvacyl/Moapar three-month formulation.
Protox Therapeutics has announced the enrolment and successful dosing of the first patient in a Phase II clinical trial evaluating PRX302 to treat benign prostatic hyperplasia, or enlarged prostate, a common and bothersome urological condition that affects over one million
Lpath has announced that the FDA, after review of the company's April 2008 investigational new drug submittal, has allowed Lpath to administer iSONEP to patients suffering from exudative age-related macular degeneration in a Phase I clinical trial.
Sanofi-Aventis has announced that findings from the landmark Athena study showed that Multaq, a potential therapy for the treatment of atrial fibrillation or atrial flutter, decreased the risk of cardiovascular hospitalizations or death from any cause by a statistically significant
Biotech firm Antisoma has entered into an agreement to acquire US-based oncology company Xanthus Pharmaceuticals, in an all-share deal valued at GBP26.8 million.
Inspire Pharmaceuticals has received $1.25 million milestone payment from Santen Pharmaceutical, related to the completion of Santen's Phase III testing of diquafosol tetrasodium, for the treatment of dry eye.
Molecular diagnostics company Asuragen has announced the CE-mark and European launch of RNARetain Pre-Analytical RNA Stabilization Solution, the company's clinically validated and RNA stabilization solution.
Abbott has launched the StarClose SE Vascular Closure System, a next-generation vessel closure device engineered to enable fast, safe and secure closure of the femoral artery access site following a catheterization procedure. StarClose SE is available in the US and
Albireo, a Swedish biotechnology company focusing on the development of therapeutics for gastrointestinal diseases, has appointed Hans Graffner, as chief medical officer.
St Jude Medical has received the FDA clearance and European CE Mark approval for new delivery tools designed to give physicians greater control and precision when placing cardiac pacing leads in heart anatomy.
